TCM
KALA icon

Towercrest Capital Management’s KALA BIO KALA Stock Holding History

Towercrest Capital Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-49
Closed -$321K – 95
2021
Q3 		$321K Buy
+49
New +$423K 0.06% 73

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Towercrest Capital Management's KALA Position: Q4 2021 in Review

Towercrest Capital Management sold out of KALA BIO (KALA) in Q4 2021, closing a stake of 49 shares — an estimated $321K sold.

Towercrest Capital Management first reported a position in KALA in Q3 2021 and held it in 1 quarter. The position peaked at $321K in Q3 2021. 79 funds tracked by Wall St. Rank hold KALA as of Q4 2021.

  • Towercrest Capital Management reported no remaining KALA BIO position as of Q4 2021 after selling out during the quarter.
  • Towercrest Capital Management sold 49 KALA BIO shares in Q4 2021, an estimated $321K.
  • Towercrest Capital Management first reported a position in KALA BIO in Q3 2021 and held it in 1 quarter.
  • Towercrest Capital Management's KALA BIO position peaked at $321K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held KALA BIO as of Q4 2021.

Based on Towercrest Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.